MersV1, PubMed, Curation, bibRecord, 000C73

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.

Identifieur interne : 000C73 ( PubMed/Curation ); précédent : 000C72; suivant : 000C74

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.

Auteurs : Naif Khalaf Alharbi [Arabie saoudite] ; Eriko Padron-Regalado [Royaume-Uni] ; Craig P. Thompson [Royaume-Uni] ; Alexandra Kupke [Allemagne] ; Daniel Wells [Royaume-Uni] ; Megan A. Sloan [Royaume-Uni] ; Keith Grehan [Royaume-Uni] ; Nigel Temperton [Royaume-Uni] ; Teresa Lambe [Royaume-Uni] ; George Warimwe [Royaume-Uni] ; Stephan Becker [Allemagne] ; Adrian V S. Hill [Royaume-Uni] ; Sarah C. Gilbert [Royaume-Uni]

Source :

Vaccine [ 1873-2518 ] ; 2017.

RBID : pubmed:28579232

Descripteurs français

English descriptors

KwdEn :
- Adenoviridae (genetics), Adenoviridae (immunology), Animals, Antibodies, Neutralizing (biosynthesis), Antibodies, Neutralizing (immunology), Antibodies, Viral (biosynthesis), Antibodies, Viral (immunology), Coronavirus Infections (immunology), Coronavirus Infections (prevention & control), Dose-Response Relationship, Immunologic, Immunity, Cellular, Immunity, Humoral, Immunogenicity, Vaccine, Mice, Middle East Respiratory Syndrome Coronavirus (genetics), Middle East Respiratory Syndrome Coronavirus (immunology), Spike Glycoprotein, Coronavirus (genetics), Spike Glycoprotein, Coronavirus (immunology), Vaccination, Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (immunology), Viral Vaccines (genetics), Viral Vaccines (immunology).
MESH :
- chemical , administration & dosage : Vaccines, Synthetic.
- chemical , biosynthesis : Antibodies, Neutralizing, Antibodies, Viral.
- genetics : Adenoviridae, Middle East Respiratory Syndrome Coronavirus, Spike Glycoprotein, Coronavirus, Viral Vaccines.
- immunology : Adenoviridae, Antibodies, Neutralizing, Antibodies, Viral, Coronavirus Infections, Middle East Respiratory Syndrome Coronavirus, Spike Glycoprotein, Coronavirus, Vaccines, Synthetic, Viral Vaccines.
- prevention & control : Coronavirus Infections.
- Animals, Dose-Response Relationship, Immunologic, Immunity, Cellular, Immunity, Humoral, Immunogenicity, Vaccine, Mice, Vaccination.

Abstract

The Middle East respiratory syndrome coronavirus (MERS-CoV) has infected more than 1900 humans, since 2012. The syndrome ranges from asymptomatic and mild cases to severe pneumonia and death. The virus is believed to be circulating in dromedary camels without notable symptoms since the 1980s. Therefore, dromedary camels are considered the only animal source of infection. Neither antiviral drugs nor vaccines are approved for veterinary or medical use despite active research on this area. Here, we developed four vaccine candidates against MERS-CoV based on ChAdOx1 and MVA viral vectors, two candidates per vector. All vaccines contained the full-length spike gene of MERS-CoV; ChAdOx1 MERS vaccines were produced with or without the leader sequence of the human tissue plasminogen activator gene (tPA) where MVA MERS vaccines were produced with tPA, but either the mH5 or F11 promoter driving expression of the spike gene. All vaccine candidates were evaluated in a mouse model in prime only or prime-boost regimens. ChAdOx1 MERS with tPA induced higher neutralising antibodies than ChAdOx1 MERS without tPA. A single dose of ChAdOx1 MERS with tPA elicited cellular immune responses as well as neutralising antibodies that were boosted to a significantly higher level by MVA MERS. The humoral immunogenicity of a single dose of ChAdOx1 MERS with tPA was equivalent to two doses of MVA MERS (also with tPA). MVA MERS with mH5 or F11 promoter induced similar antibody levels; however, F11 promoter enhanced the cellular immunogenicity of MVA MERS to significantly higher magnitudes. In conclusion, our study showed that MERS-CoV vaccine candidates could be optimized by utilising different viral vectors, various genetic designs of the vectors, or different regimens to increase immunogenicity. ChAdOx1 and MVA vectored vaccines have been safely evaluated in camels and humans and these MERS vaccine candidates should now be tested in camels and in clinical trials.

DOI: 10.1016/j.vaccine.2017.05.032
PubMed: 28579232

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000C73

Links to Exploration step

pubmed:28579232

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.</title>
<author><name sortKey="Alharbi, Naif Khalaf" sort="Alharbi, Naif Khalaf" uniqKey="Alharbi N" first="Naif Khalaf" last="Alharbi">Naif Khalaf Alharbi</name>
<affiliation wicri:level="1"><nlm:affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. Electronic address: harbina2@ngha.med.sa.</nlm:affiliation>
<country xml:lang="fr">Arabie saoudite</country>
<wicri:regionArea>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK; King Abdullah International Medical Research Center, Riyadh</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Padron Regalado, Eriko" sort="Padron Regalado, Eriko" uniqKey="Padron Regalado E" first="Eriko" last="Padron-Regalado">Eriko Padron-Regalado</name>
<affiliation wicri:level="1"><nlm:affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Jenner Institute, University of Oxford, Oxford OX3 7DQ</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Thompson, Craig P" sort="Thompson, Craig P" uniqKey="Thompson C" first="Craig P" last="Thompson">Craig P. Thompson</name>
<affiliation wicri:level="1"><nlm:affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK; Department of Zoology, University of Oxford, Oxford, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK; Department of Zoology, University of Oxford, Oxford</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kupke, Alexandra" sort="Kupke, Alexandra" uniqKey="Kupke A" first="Alexandra" last="Kupke">Alexandra Kupke</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Virology, Philipps University of Marburg, Marburg, Germany; German Center for Infection Research, TTU Emerging Infections, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Virology, Philipps University of Marburg, Marburg, Germany; German Center for Infection Research, TTU Emerging Infections</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wells, Daniel" sort="Wells, Daniel" uniqKey="Wells D" first="Daniel" last="Wells">Daniel Wells</name>
<affiliation wicri:level="1"><nlm:affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Jenner Institute, University of Oxford, Oxford OX3 7DQ</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sloan, Megan A" sort="Sloan, Megan A" uniqKey="Sloan M" first="Megan A" last="Sloan">Megan A. Sloan</name>
<affiliation wicri:level="1"><nlm:affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Jenner Institute, University of Oxford, Oxford OX3 7DQ</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Grehan, Keith" sort="Grehan, Keith" uniqKey="Grehan K" first="Keith" last="Grehan">Keith Grehan</name>
<affiliation wicri:level="1"><nlm:affiliation>Viral Pseudotype Unit, School of Pharmacy, University of Kent, Chatham Maritime, Kent ME4 4TB, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Viral Pseudotype Unit, School of Pharmacy, University of Kent, Chatham Maritime, Kent ME4 4TB</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Temperton, Nigel" sort="Temperton, Nigel" uniqKey="Temperton N" first="Nigel" last="Temperton">Nigel Temperton</name>
<affiliation wicri:level="1"><nlm:affiliation>Viral Pseudotype Unit, School of Pharmacy, University of Kent, Chatham Maritime, Kent ME4 4TB, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Viral Pseudotype Unit, School of Pharmacy, University of Kent, Chatham Maritime, Kent ME4 4TB</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lambe, Teresa" sort="Lambe, Teresa" uniqKey="Lambe T" first="Teresa" last="Lambe">Teresa Lambe</name>
<affiliation wicri:level="1"><nlm:affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Jenner Institute, University of Oxford, Oxford OX3 7DQ</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Warimwe, George" sort="Warimwe, George" uniqKey="Warimwe G" first="George" last="Warimwe">George Warimwe</name>
<affiliation wicri:level="1"><nlm:affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Jenner Institute, University of Oxford, Oxford OX3 7DQ</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Becker, Stephan" sort="Becker, Stephan" uniqKey="Becker S" first="Stephan" last="Becker">Stephan Becker</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Virology, Philipps University of Marburg, Marburg, Germany; German Center for Infection Research, TTU Emerging Infections, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Virology, Philipps University of Marburg, Marburg, Germany; German Center for Infection Research, TTU Emerging Infections</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hill, Adrian V S" sort="Hill, Adrian V S" uniqKey="Hill A" first="Adrian V S" last="Hill">Adrian V S. Hill</name>
<affiliation wicri:level="1"><nlm:affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Jenner Institute, University of Oxford, Oxford OX3 7DQ</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gilbert, Sarah C" sort="Gilbert, Sarah C" uniqKey="Gilbert S" first="Sarah C" last="Gilbert">Sarah C. Gilbert</name>
<affiliation wicri:level="1"><nlm:affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Jenner Institute, University of Oxford, Oxford OX3 7DQ</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28579232</idno>
<idno type="pmid">28579232</idno>
<idno type="doi">10.1016/j.vaccine.2017.05.032</idno>
<idno type="wicri:Area/PubMed/Corpus">000C73</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C73</idno>
<idno type="wicri:Area/PubMed/Curation">000C73</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C73</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.</title>
<author><name sortKey="Alharbi, Naif Khalaf" sort="Alharbi, Naif Khalaf" uniqKey="Alharbi N" first="Naif Khalaf" last="Alharbi">Naif Khalaf Alharbi</name>
<affiliation wicri:level="1"><nlm:affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. Electronic address: harbina2@ngha.med.sa.</nlm:affiliation>
<country xml:lang="fr">Arabie saoudite</country>
<wicri:regionArea>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK; King Abdullah International Medical Research Center, Riyadh</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Padron Regalado, Eriko" sort="Padron Regalado, Eriko" uniqKey="Padron Regalado E" first="Eriko" last="Padron-Regalado">Eriko Padron-Regalado</name>
<affiliation wicri:level="1"><nlm:affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Jenner Institute, University of Oxford, Oxford OX3 7DQ</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Thompson, Craig P" sort="Thompson, Craig P" uniqKey="Thompson C" first="Craig P" last="Thompson">Craig P. Thompson</name>
<affiliation wicri:level="1"><nlm:affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK; Department of Zoology, University of Oxford, Oxford, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK; Department of Zoology, University of Oxford, Oxford</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kupke, Alexandra" sort="Kupke, Alexandra" uniqKey="Kupke A" first="Alexandra" last="Kupke">Alexandra Kupke</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Virology, Philipps University of Marburg, Marburg, Germany; German Center for Infection Research, TTU Emerging Infections, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Virology, Philipps University of Marburg, Marburg, Germany; German Center for Infection Research, TTU Emerging Infections</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wells, Daniel" sort="Wells, Daniel" uniqKey="Wells D" first="Daniel" last="Wells">Daniel Wells</name>
<affiliation wicri:level="1"><nlm:affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Jenner Institute, University of Oxford, Oxford OX3 7DQ</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sloan, Megan A" sort="Sloan, Megan A" uniqKey="Sloan M" first="Megan A" last="Sloan">Megan A. Sloan</name>
<affiliation wicri:level="1"><nlm:affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Jenner Institute, University of Oxford, Oxford OX3 7DQ</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Grehan, Keith" sort="Grehan, Keith" uniqKey="Grehan K" first="Keith" last="Grehan">Keith Grehan</name>
<affiliation wicri:level="1"><nlm:affiliation>Viral Pseudotype Unit, School of Pharmacy, University of Kent, Chatham Maritime, Kent ME4 4TB, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Viral Pseudotype Unit, School of Pharmacy, University of Kent, Chatham Maritime, Kent ME4 4TB</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Temperton, Nigel" sort="Temperton, Nigel" uniqKey="Temperton N" first="Nigel" last="Temperton">Nigel Temperton</name>
<affiliation wicri:level="1"><nlm:affiliation>Viral Pseudotype Unit, School of Pharmacy, University of Kent, Chatham Maritime, Kent ME4 4TB, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Viral Pseudotype Unit, School of Pharmacy, University of Kent, Chatham Maritime, Kent ME4 4TB</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lambe, Teresa" sort="Lambe, Teresa" uniqKey="Lambe T" first="Teresa" last="Lambe">Teresa Lambe</name>
<affiliation wicri:level="1"><nlm:affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Jenner Institute, University of Oxford, Oxford OX3 7DQ</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Warimwe, George" sort="Warimwe, George" uniqKey="Warimwe G" first="George" last="Warimwe">George Warimwe</name>
<affiliation wicri:level="1"><nlm:affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Jenner Institute, University of Oxford, Oxford OX3 7DQ</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Becker, Stephan" sort="Becker, Stephan" uniqKey="Becker S" first="Stephan" last="Becker">Stephan Becker</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Virology, Philipps University of Marburg, Marburg, Germany; German Center for Infection Research, TTU Emerging Infections, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Virology, Philipps University of Marburg, Marburg, Germany; German Center for Infection Research, TTU Emerging Infections</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hill, Adrian V S" sort="Hill, Adrian V S" uniqKey="Hill A" first="Adrian V S" last="Hill">Adrian V S. Hill</name>
<affiliation wicri:level="1"><nlm:affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Jenner Institute, University of Oxford, Oxford OX3 7DQ</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gilbert, Sarah C" sort="Gilbert, Sarah C" uniqKey="Gilbert S" first="Sarah C" last="Gilbert">Sarah C. Gilbert</name>
<affiliation wicri:level="1"><nlm:affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Jenner Institute, University of Oxford, Oxford OX3 7DQ</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenoviridae (genetics)</term>
<term>Adenoviridae (immunology)</term>
<term>Animals</term>
<term>Antibodies, Neutralizing (biosynthesis)</term>
<term>Antibodies, Neutralizing (immunology)</term>
<term>Antibodies, Viral (biosynthesis)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Dose-Response Relationship, Immunologic</term>
<term>Immunity, Cellular</term>
<term>Immunity, Humoral</term>
<term>Immunogenicity, Vaccine</term>
<term>Mice</term>
<term>Middle East Respiratory Syndrome Coronavirus (genetics)</term>
<term>Middle East Respiratory Syndrome Coronavirus (immunology)</term>
<term>Spike Glycoprotein, Coronavirus (genetics)</term>
<term>Spike Glycoprotein, Coronavirus (immunology)</term>
<term>Vaccination</term>
<term>Vaccines, Synthetic (administration & dosage)</term>
<term>Vaccines, Synthetic (immunology)</term>
<term>Viral Vaccines (genetics)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adenoviridae (génétique)</term>
<term>Adenoviridae (immunologie)</term>
<term>Animaux</term>
<term>Anticorps antiviraux (biosynthèse)</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Anticorps neutralisants (biosynthèse)</term>
<term>Anticorps neutralisants (immunologie)</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (génétique)</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie)</term>
<term>Glycoprotéine de spicule des coronavirus (génétique)</term>
<term>Glycoprotéine de spicule des coronavirus (immunologie)</term>
<term>Immunité cellulaire</term>
<term>Immunité humorale</term>
<term>Immunogénicité des vaccins</term>
<term>Infections à coronavirus ()</term>
<term>Infections à coronavirus (immunologie)</term>
<term>Relation dose-réponse (immunologie)</term>
<term>Souris</term>
<term>Vaccination</term>
<term>Vaccins antiviraux (génétique)</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Vaccins synthétiques (administration et posologie)</term>
<term>Vaccins synthétiques (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines, Synthetic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins synthétiques</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps neutralisants</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Adenoviridae</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Adenoviridae</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Adenoviridae</term>
<term>Anticorps antiviraux</term>
<term>Anticorps neutralisants</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Infections à coronavirus</term>
<term>Vaccins antiviraux</term>
<term>Vaccins synthétiques</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Adenoviridae</term>
<term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
<term>Coronavirus Infections</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Vaccines, Synthetic</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Dose-Response Relationship, Immunologic</term>
<term>Immunity, Cellular</term>
<term>Immunity, Humoral</term>
<term>Immunogenicity, Vaccine</term>
<term>Mice</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Immunité cellulaire</term>
<term>Immunité humorale</term>
<term>Immunogénicité des vaccins</term>
<term>Infections à coronavirus</term>
<term>Relation dose-réponse (immunologie)</term>
<term>Souris</term>
<term>Vaccination</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The Middle East respiratory syndrome coronavirus (MERS-CoV) has infected more than 1900 humans, since 2012. The syndrome ranges from asymptomatic and mild cases to severe pneumonia and death. The virus is believed to be circulating in dromedary camels without notable symptoms since the 1980s. Therefore, dromedary camels are considered the only animal source of infection. Neither antiviral drugs nor vaccines are approved for veterinary or medical use despite active research on this area. Here, we developed four vaccine candidates against MERS-CoV based on ChAdOx1 and MVA viral vectors, two candidates per vector. All vaccines contained the full-length spike gene of MERS-CoV; ChAdOx1 MERS vaccines were produced with or without the leader sequence of the human tissue plasminogen activator gene (tPA) where MVA MERS vaccines were produced with tPA, but either the mH5 or F11 promoter driving expression of the spike gene. All vaccine candidates were evaluated in a mouse model in prime only or prime-boost regimens. ChAdOx1 MERS with tPA induced higher neutralising antibodies than ChAdOx1 MERS without tPA. A single dose of ChAdOx1 MERS with tPA elicited cellular immune responses as well as neutralising antibodies that were boosted to a significantly higher level by MVA MERS. The humoral immunogenicity of a single dose of ChAdOx1 MERS with tPA was equivalent to two doses of MVA MERS (also with tPA). MVA MERS with mH5 or F11 promoter induced similar antibody levels; however, F11 promoter enhanced the cellular immunogenicity of MVA MERS to significantly higher magnitudes. In conclusion, our study showed that MERS-CoV vaccine candidates could be optimized by utilising different viral vectors, various genetic designs of the vectors, or different regimens to increase immunogenicity. ChAdOx1 and MVA vectored vaccines have been safely evaluated in camels and humans and these MERS vaccine candidates should now be tested in camels and in clinical trials.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28579232</PMID>
<DateCompleted><Year>2018</Year>
<Month>03</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>35</Volume>
<Issue>30</Issue>
<PubDate><Year>2017</Year>
<Month>06</Month>
<Day>27</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.</ArticleTitle>
<Pagination><MedlinePgn>3780-3788</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0264-410X(17)30656-4</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2017.05.032</ELocationID>
<Abstract><AbstractText>The Middle East respiratory syndrome coronavirus (MERS-CoV) has infected more than 1900 humans, since 2012. The syndrome ranges from asymptomatic and mild cases to severe pneumonia and death. The virus is believed to be circulating in dromedary camels without notable symptoms since the 1980s. Therefore, dromedary camels are considered the only animal source of infection. Neither antiviral drugs nor vaccines are approved for veterinary or medical use despite active research on this area. Here, we developed four vaccine candidates against MERS-CoV based on ChAdOx1 and MVA viral vectors, two candidates per vector. All vaccines contained the full-length spike gene of MERS-CoV; ChAdOx1 MERS vaccines were produced with or without the leader sequence of the human tissue plasminogen activator gene (tPA) where MVA MERS vaccines were produced with tPA, but either the mH5 or F11 promoter driving expression of the spike gene. All vaccine candidates were evaluated in a mouse model in prime only or prime-boost regimens. ChAdOx1 MERS with tPA induced higher neutralising antibodies than ChAdOx1 MERS without tPA. A single dose of ChAdOx1 MERS with tPA elicited cellular immune responses as well as neutralising antibodies that were boosted to a significantly higher level by MVA MERS. The humoral immunogenicity of a single dose of ChAdOx1 MERS with tPA was equivalent to two doses of MVA MERS (also with tPA). MVA MERS with mH5 or F11 promoter induced similar antibody levels; however, F11 promoter enhanced the cellular immunogenicity of MVA MERS to significantly higher magnitudes. In conclusion, our study showed that MERS-CoV vaccine candidates could be optimized by utilising different viral vectors, various genetic designs of the vectors, or different regimens to increase immunogenicity. ChAdOx1 and MVA vectored vaccines have been safely evaluated in camels and humans and these MERS vaccine candidates should now be tested in camels and in clinical trials.</AbstractText>
<CopyrightInformation>Copyright © 2017. Published by Elsevier Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alharbi</LastName>
<ForeName>Naif Khalaf</ForeName>
<Initials>NK</Initials>
<AffiliationInfo><Affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. Electronic address: harbina2@ngha.med.sa.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Padron-Regalado</LastName>
<ForeName>Eriko</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Thompson</LastName>
<ForeName>Craig P</ForeName>
<Initials>CP</Initials>
<AffiliationInfo><Affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK; Department of Zoology, University of Oxford, Oxford, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kupke</LastName>
<ForeName>Alexandra</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Institute of Virology, Philipps University of Marburg, Marburg, Germany; German Center for Infection Research, TTU Emerging Infections, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wells</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sloan</LastName>
<ForeName>Megan A</ForeName>
<Initials>MA</Initials>
<AffiliationInfo><Affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Grehan</LastName>
<ForeName>Keith</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Viral Pseudotype Unit, School of Pharmacy, University of Kent, Chatham Maritime, Kent ME4 4TB, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Temperton</LastName>
<ForeName>Nigel</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Viral Pseudotype Unit, School of Pharmacy, University of Kent, Chatham Maritime, Kent ME4 4TB, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lambe</LastName>
<ForeName>Teresa</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Warimwe</LastName>
<ForeName>George</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Becker</LastName>
<ForeName>Stephan</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Institute of Virology, Philipps University of Marburg, Marburg, Germany; German Center for Infection Research, TTU Emerging Infections, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hill</LastName>
<ForeName>Adrian V S</ForeName>
<Initials>AVS</Initials>
<AffiliationInfo><Affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gilbert</LastName>
<ForeName>Sarah C</ForeName>
<Initials>SC</Initials>
<AffiliationInfo><Affiliation>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_14111</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>06</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C560489">MVA vaccine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000256" MajorTopicYN="N">Adenoviridae</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004306" MajorTopicYN="N">Dose-Response Relationship, Immunologic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007111" MajorTopicYN="Y">Immunity, Cellular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Adenoviral vector</Keyword>
<Keyword MajorTopicYN="Y">ChAdOx1</Keyword>
<Keyword MajorTopicYN="Y">Coronavirus</Keyword>
<Keyword MajorTopicYN="Y">Immunogenicity</Keyword>
<Keyword MajorTopicYN="Y">MERS-CoV</Keyword>
<Keyword MajorTopicYN="Y">MVA</Keyword>
<Keyword MajorTopicYN="Y">Poxviral vector</Keyword>
<Keyword MajorTopicYN="Y">Prime boost</Keyword>
<Keyword MajorTopicYN="Y">Vaccination</Keyword>
<Keyword MajorTopicYN="Y">Vaccine</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year>
<Month>03</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2017</Year>
<Month>04</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>05</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>6</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2018</Year>
<Month>3</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>6</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28579232</ArticleId>
<ArticleId IdType="pii">S0264-410X(17)30656-4</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2017.05.032</ArticleId>
<ArticleId IdType="pmc">PMC5516308</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Nat Med. 2008 Aug;14(8):819-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18660818</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2013 Aug 29;369(9):884-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23923992</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2012;7(7):e40385</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22808149</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Rev Med Virol. 2017 Mar;27(2):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27786402</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2008 Apr;82(8):3822-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18256155</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>mBio. 2014 Feb 25;5(2):e00884-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24570370</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Microbes Infect. 2016 Nov 9;5(11):e113</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27826140</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>EBioMedicine. 2015 Aug 18;2(10):1438-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26629538</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Transl Med. 2015 Aug 19;7(301):301ra132</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26290414</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Expert Rev Vaccines. 2013 Dec;12(12):1395-416</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24168097</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2013 Sep 6;31(39):4241-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23523410</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Mol Ther. 2014 Mar;22(3):668-674</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24374965</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet Infect Dis. 2013 Oct;13(10):859-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23933067</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biotechnol Bioeng. 2012 Mar;109(3):719-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22252512</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2013 Oct;9(10):2095-102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23941868</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Microbiol. 2010 Jan;8(1):62-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19966816</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2013 Nov;87(21):11950-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23986586</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Euro Surveill. 2014 Jun 12;19(23):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24957744</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Rep. 2016 May 05;6:25359</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27146253</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Rep. 2016 Feb 05;6:20617</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26847478</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Exp Med. 2005 Jan 17;201(2):201-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15657290</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Viruses. 2016 Aug 19;8(8):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27548203</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol Methods. 2008 Dec;154(1-2):121-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18789973</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Infect Dis. 2016 Feb 15;62(4):477-483</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26565003</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Commun. 2015 Jul 28;6:7712</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26218507</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vector Borne Zoonotic Dis. 2017 Feb;17(2):155-159</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28009529</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2015 Aug;89(16):8651-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26018172</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2015 Dec;21(12):2197-200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26584223</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Euro Surveill. 2013 Dec 12;18(50):20662</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24342516</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2016 Jan;22(1):49-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26692185</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>MethodsX. 2015 Oct 13;2:379-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26587388</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Front Vet Sci. 2016 Oct 05;3:88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27761437</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2016 Jan 2;34(1):49-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26616553</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2006 Jul;80(13):6318-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16775319</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Microbes Infect. 2017 Jan 4;6(1):e1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28050021</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Euro Surveill. 2015;20(37):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26536463</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2015 Feb 26;372(9):846-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25714162</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virol J. 2013 Dec 05;10:349</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24304565</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Zoonoses Public Health. 2016 Feb;63(1):1-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25545147</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Am J Epidemiol. 2016 Apr 1;183(7):657-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26851269</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Curr. 2013 Nov 12;5:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24270606</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2014 Dec;20(12):2093-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25425139</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2016 Jan 1;351(6268):77-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26678878</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2015 Dec;21(12):2186-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26583829</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2008 Feb 20;3(2):e1638</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18286194</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Euro Surveill. 2013 Dec 12;18(50):20659</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24342517</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2017 Feb;23(2):232-240</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27901465</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Euro Surveill. 2013 Sep 05;18(36):pii=20574</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24079378</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C73 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000C73 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:28579232
   |texte=   ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:28579232" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki